Insider Selling: Stevanato Group (NYSE:STVN) CFO Sells €84,558.81 in Stock

Stevanato Group S.p.A. (NYSE:STVN) CFO Lago Marco Dal sold 4,209 shares of Stevanato Group stock in a transaction on Friday, August 7th. The shares were sold at an average price of €20.09, for a total value of €84,558.81. Following the transaction, the chief financial officer owned 81,144 shares in the company, valued at approximately €1,630,182.96. This trade represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stevanato Group Price Performance

Shares of STVN traded up €0.38 during midday trading on Monday, reaching €20.65. The stock had a trading volume of 501,629 shares, compared to its average volume of 541,629. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. The company has a market capitalization of $6.25 billion, a P/E ratio of 36.87, a P/E/G ratio of 1.70 and a beta of 0.77. The firm’s 50 day moving average price is €18.80 and its 200-day moving average price is €16.97. Stevanato Group S.p.A. has a 52 week low of €12.89 and a 52 week high of €28.00.

Stevanato Group (NYSE:STVN) last announced its earnings results on Friday, May 8th. The company reported €0.11 earnings per share for the quarter, missing the consensus estimate of €0.12 by (€0.01). Stevanato Group had a net margin of 10.99% and a return on equity of 10.43%. The firm had revenue of €273.57 million for the quarter. During the same period in the prior year, the company earned $0.10 earnings per share. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. On average, analysts forecast that Stevanato Group S.p.A. will post 0.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

STVN has been the topic of a number of research reports. Wolfe Research assumed coverage on shares of Stevanato Group in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $21.00 target price on the stock. Weiss Ratings upgraded shares of Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 16th. Finally, TD Cowen raised Stevanato Group to a “strong-buy” rating in a report on Wednesday, June 17th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Institutional Trading of Stevanato Group

A number of hedge funds have recently bought and sold shares of the company. GW&K Investment Management LLC increased its position in shares of Stevanato Group by 76.2% in the fourth quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock worth $49,000 after acquiring an additional 1,055 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of Stevanato Group by 22.6% in the 1st quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock valued at $58,000 after acquiring an additional 773 shares in the last quarter. State of Wyoming boosted its stake in Stevanato Group by 39,216.7% in the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock worth $58,000 after purchasing an additional 2,353 shares during the period. Quantbot Technologies LP acquired a new position in Stevanato Group in the 3rd quarter worth approximately $68,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Stevanato Group by 1,268.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock worth $112,000 after buying an additional 4,250 shares during the period.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.